Core Insights - The approval of the non-covalent BTK inhibitor, Jebatilib (Pirtobrutinib), for a new indication in treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously undergone at least one systemic treatment including BTK inhibitors is a significant milestone for the company and the industry [1][2] Group 1: Regulatory Approval - Jebatilib has received approval from the National Medical Products Administration (NMPA) in China for a new indication in CLL/SLL treatment [1] - The drug was previously approved by the FDA in January 2023 and is set to be available for adult patients with relapsed or refractory mantle cell lymphoma (MCL) in China starting October 2024 [1] Group 2: Clinical Research - The new indication approval is based on the results of the international, multicenter, randomized controlled BRUIN CLL-321 Phase III study, which included 238 patients [2] - The study demonstrated that Jebatilib significantly extended the median progression-free survival (PFS) to 14.0 months compared to 8.7 months for the control group, with a hazard ratio (HR) of 0.54 [2] - The treatment-related discontinuation rate was lower for Jebatilib at 5.2% compared to 21.1% for the control group, highlighting its efficacy and tolerability in patients previously treated with covalent BTK inhibitors [2] Group 3: Market Impact - The approval of Jebatilib for CLL/SLL represents a major breakthrough in the field, allowing Chinese patients to benefit from this global innovation [2] - The company aims to leverage its leading brand and expertise in oncology to accelerate the accessibility of this innovative therapy for cancer patients in need [2]
信达生物(01801)：捷帕力(匹妥布替尼)在中国获批复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤适应症